338 related articles for article (PubMed ID: 33322163)
41. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract][Full Text] [Related]
42. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
[TBL] [Abstract][Full Text] [Related]
43. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
44. Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.
Lalani AA; Heng DYC; Basappa NS; Wood L; Iqbal N; McLeod D; Soulières D; Kollmannsberger C
Ther Adv Med Oncol; 2022; 14():17588359221108685. PubMed ID: 35782749
[TBL] [Abstract][Full Text] [Related]
45. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
46. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
47. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
48. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Ricci AD; Grilli G; Greco A; Montironi R; Ardizzoni A; Massari F
Immunotherapy; 2021 Jun; 13(9):783-793. PubMed ID: 33906376
[No Abstract] [Full Text] [Related]
49. Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.
Borchiellini D; Maillet D
Bull Cancer; 2022 May; 109(2S):2S4-2S18. PubMed ID: 35760470
[TBL] [Abstract][Full Text] [Related]
50. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
51. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
[TBL] [Abstract][Full Text] [Related]
52. Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
Granet-Vaissiere E; Lefort F; Domblides C; Larroquette M; Ravaud A; Bernhard JC; Gross-Goupil M
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831392
[TBL] [Abstract][Full Text] [Related]
53. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.
Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI
Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
[TBL] [Abstract][Full Text] [Related]
56. Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study.
Sobu R; Numakura K; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2023 Feb; 12(4):4100-4109. PubMed ID: 36200612
[TBL] [Abstract][Full Text] [Related]
57. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Tao L; Zhang H; An G; Lan H; Xu Y; Ge Y; Yao J
Front Oncol; 2021; 11():739263. PubMed ID: 34722290
[TBL] [Abstract][Full Text] [Related]
58. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
59. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
Beypınar I; Sözel Y; Önder AH
Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
[TBL] [Abstract][Full Text] [Related]
60. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma.
McKay RR; Bossé D; Choueiri TK
J Clin Oncol; 2018 Oct; ():JCO2018790253. PubMed ID: 30372392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]